A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors

被引:0
作者
Jill E. Lavigne
Charles Heckler
Jennifer L. Mathews
Oxana Palesh
Jeffrey J. Kirshner
Raymond Lord
Andrew Jacobs
Eric Amos
Gary R. Morrow
Karen Mustian
机构
[1] St. John Fisher College,Wegmans School of Pharmacy
[2] James P. Wilmot Cancer Center,Department of Radiation Oncology
[3] University of Rochester Medical Center,Department of Psychiatry
[4] Stanford University Medical School,Community Clinical Oncology Base
[5] James P. Wilmot Cancer Center,undefined
[6] University of Rochester Medical Center,undefined
来源
Breast Cancer Research and Treatment | 2012年 / 136卷
关键词
Gabapentin; Neurontin; Anti-epileptics; Breast; Cancer; Anxiety; Randomized controlled trial; Cancer survivorship;
D O I
暂无
中图分类号
学科分类号
摘要
Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
引用
收藏
页码:479 / 486
页数:7
相关论文
共 101 条
[1]  
Chalasani P(2010)Caring for the breast cancer survivor: a guide for primary care physicians Am J Med 123 489-495
[2]  
Downey L(2006)American Society of Clinical Oncology 2006 update of breast cancer follow-up and management guidelines in the adjuvant setting J Clin Oncol 24 5091-5097
[3]  
Stopeck AT(2010)Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients Psychosomatics 51 112-123
[4]  
Khatcheressian J(2010)What do predict anxiety and depression in breast cancer patients? A follow-up study Soc Psychiatry Psychiatr Epidemiol 45 355-361
[5]  
Wolff A(2009)Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey J Clin Oncol 27 6172-6179
[6]  
Smith T(2007)Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection Ann Intern Med 146 317-325
[7]  
Hartl K(2010)The pharmacologic treatment of anxiety disorders: a review of progress J Clin Psychiatry 71 7-149
[8]  
Schennach R(2004)Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled multi-center study J Clin Psychopharmacol 24 141-782
[9]  
Muller M(2006)Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine J Clin Psychiatry 67 771-1036
[10]  
Engel J(2006)Clinical practice: social anxiety disorder N Engl J Med 355 1029-47